ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Making presentation.

<< Previous

Bullboard Posts

Next >>

Comment by Alex1726on Jul 27, 2021 8:26pm

57 Views

Post# 33614649

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Making presentation.

Bien oui mon ti coune , continue a nous poster tes idioties , j imagine que tu comprend ce qu j ecris puisque tu repliques . tu nous diras LA SEMAINE PROCAHINE SI FEDELITY A ET UN ACHETEUR OU NON. VA JOUER AVEC TA BITE MOLLE

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season